Cecilia Furlong: Great, good afternoon, and thank you for taking the question. I wanted to start with ProTrieve. If you could comment really where you are at this point in the full market release, but then also what you’re seeing to-date in terms of use with competitive products? And then just second product related question, if you could comment to just across your chronic venous disease toolkit, new products currently plan to launch this year?
Drew Hykes: Sure, thanks for those, Cecilia. So relative to ProTrieve, we are I don’t know four months into the full market release. So, we’re clearly still working to gain a VAC approval for that product. We’ve got that products stocked at this point in less than 50% of our account base. But we’re getting very good feedback, enthusiastic feedback from physicians. It does a very effective job at addressing a pretty significant unmet need for complex DVT procedures where they’re at risk of embolizing clot and causing APE. So we like what we’re seeing so far. The fact that we’ve priced it outside of the, per procedure price model gives us some nice incremental revenue opportunity on top of the clinical impact that it’s having.
But again, we’re still in the relative early phases of navigating our way through VAC approvals and getting the product fully stocked across our entire account base. Relative to CBD, you know that we’re already helping some of those patients with ClotTriever BOLD, although BOLD wasn’t necessarily designed specifically for that group of patients that has indeed provided some utility and some relief for those patients. And then we’ve got a series of additional tools that we’ll be adding to the CBD toolkit as we move through the rest of this year and looking out further beyond that. We’ve talked in a fair amount of detail about REVCORE, which is going to be the first of those new incremental tools that was one of the products that we shared at the Investor Day for instance back in September.
That product will be coming out here in the first half of this year and will be kind of the second addition to that CBD toolkit alongside BOLD. And then as you look out further into the end of this year and into next year, we’ll have additional tools that we will be adding to that toolkit just like you’ve seen us execute with FlowTriever and ClotTriever.
Cecilia Furlong: Great. And if I could follow-up also just on gross margins, how we should think about 2023 versus the long-term outlook for from mid-80s factoring in how you’re thinking about OUS expansion, new product launches and also just the per procedure pricing impact on margins?
Mitch Hill: Yes, thank you, Cecilia. I’ll try to get started with that one. So the number you saw for Q4 of last year is something that we believe – it was something we planned for essentially as a result of the additions to the FlowTriever toolkit and as well as some of the operating leverage issues we’ve dealt with in our manufacturing facility. The longer term view towards gross margins is kind of in that low to mid-80s sort of ZIP code, I would call it. And I think it’ll be a very gradual sort of migration towards that point. The factors that will contribute to that are the ones that you’ve mentioned there. Some of the products that we’ll introduce in the future have a lower gross margin profile than the two products that primarily drive that today, the ClotTriever and the FlowTriever.
The international side of the business is something that has sort of it detracts from the current gross margin profile of the business, but we’re committed to serve patients throughout the world. So it’s something we really want to do. We do continue to evaluate opportunities to sort of work against that. We’re consistently looking for opportunities to basically sell based on the kind of the value bundle, if you will of our products. And so, we look for opportunities to take price. And we also look for opportunities to change our gross margin through some of our manufacturing purchasing and other things that we can do to sort of reduce the cost of goods sold for the product as we go along.
